AFT Pharmaceuticals Limited has reported strong growth across all regions and product lines in their financial results for the year ending 31 March 2022.
Operating revenue increased 15.2% to $130.3 million, gross profit increased 26.7% to $61.8 million, and operating profit rose strongly to $20.4 million from the prior year.
AFT’s flagship IP commercialisation programme, Maxigesic, is now sold in 46 countries, with the tablet form of the medication being registered in multiple markets in Asia and South America.
The company has also strengthened its R&D pipeline, with multiple projects in dermatology, gastro-intestinal health, and medicinal CBD.
A dividend policy has also been announced, with the Board's intention to pay a dividend in the 20-30% range of normalised net profit after tax in relation to the FY2023 financial year.
With easing of pandemic restrictions, a robust new product pipeline, and ongoing Maxigesic commercialisation program, AFT Pharmaceuticals is looking forward to continuing its strong growth prospects.
See more
